Serum carboxymethyllysine, an advanced glycation end product, and age-related macular degeneration: The age, gene/environment susceptibility- Reykjavik study

JAMA Ophthalmology

Volumn 132, Issue 4, 2014, Pages 464-470

  Semba, Richard D ^a   Cotch, Mary Frances ^b   Gudnason, Vilmundur ^c,d   Eiriksdottir, Gudny ^c   Harris, Tamara B ^e   Sun, Kai ^a   Klein, Ronald ^f   Jonasson, Fridbert ^d,g   Ferrucci, Luigi ^e   Schaumberg, Debra A ^h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c ICELANDIC HEART ASSOCIATION   (Iceland)

^d UNIVERSITY OF ICELAND   (Iceland)

^e NATIONAL INSTITUTE ON AGING   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VISUAL PIGMENT;

AGED; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DEPIGMENTATION; DIABETES MELLITUS; DRUSEN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE ENVIRONMENT INTERACTION; GEOGRAPHIC ATROPHY; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PIGMENT EPITHELIUM; POPULATION RESEARCH; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SMOKING;

AGE FACTORS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE-ENVIRONMENT INTERACTION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; ICELAND; LOGISTIC MODELS; LYSINE; MACULAR DEGENERATION; MALE; PREVALENCE; RISK FACTORS; VISUAL ACUITY;

EID: 84898669479     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.7664     Document Type: Article

References (42)

1. Jager RD, MielerWF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008; 358 (24): 2606-2617.
2. Friedman DS, O'Colmain BJ, Munoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122 (4): 564-572.
3. AMD Alliance International. The global economic cost of visual impairment. http://www.amdalliance .org/global-economic-cost-of-visual- impairment- 2010.html. Accessed November 8, 2011.
4. SmithW, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001; 108 (4): 697-704.
5. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking: the Rotterdam Study. Arch Ophthalmol. 1996; 114 (10): 1193-1196.
6. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology. 2004; 111 (7): 1280-1287.
7. ChangMA, Bressler SB, Munoz B, West SK. Racial differences and other risk factors for incidence and progression of age-related macular degeneration: Salisbury Eye Evaluation (SEE) Project. Invest Ophthalmol Vis Sci. 2008; 49 (6): 2395-2402.
8. Schachat AP, Hyman L, Leske MC, Connell AMS, Wu SY; Barbados Eye Study Group. Features of age-related macular degeneration in a black population. Arch Ophthalmol. 1995; 113 (6): 728-735.
9. Flood V, SmithW, Wang JJ, Manzi F, Webb K, Mitchell P. Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2002; 109 (12): 2272-2278.
10. ChristenWG, Schaumberg DA, Glynn RJ, Buring JE. Dietary σ-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol. 2011; 129 (7): 921-929.
11. Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE, Spector TD. Genetic influence on early age-related maculopathy: a twin study. Ophthalmology. 2002; 109 (4): 730-736.
12. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997; 123 (2): 199-206.
13. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005; 308 (5720): 421-424.
14. Zareparsi S, Branham KE, LiM, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet. 2005; 77 (1): 149-153.
15. Schaumberg DA, Hankinson SE, Guo Q, Rimm E, Hunter DJ. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol. 2007; 125 (1): 55-62.
16. Leveziel N, Tilleul J, Puche N, et al. Genetic factors associated with age-related macular degeneration. Ophthalmologica. 2011; 226 (3): 87-102.
17. Deangelis MM, Silveira AC, Carr EA, Kim IK. Genetics of age-related macular degeneration: current concepts, future directions. Semin Ophthalmol. 2011; 26 (3): 77-93.
18. Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci. 2010; 65 (9): 963-975.
19. Handa JT, Matsunaga A, Aotaki-Keen A, Lutty GA, Hjelmeland LM. Immunohistochemical evidence for deposition of advanced glycation end products (AGEs) in Bruch's membrane and choroid with age. Invest Ophthalmol Vis Sci. 1998; 39 (4): S370.
20. Ishibashi T, Murata T, Hangai M, et al. Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol. 1998; 116 (12): 1629-1632.
21. Howes KA, Liu Y, Dunaief JL, et al. Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004; 45 (10): 3713-3720.
22. Yamada Y, Ishibashi K, Ishibashi K, et al. The expression of advanced glycation endproduct receptors in RPE cells associated with basal deposits in human maculas. Exp Eye Res. 2006; 82 (5): 840-848.
23. MaW, Lee SE, Guo J, et al. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2007; 48 (3): 1355-1361.
24. Ni J, Yuan X, Gu J, et al; Clinical Genomic and Proteomic AMD Study Group. Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics. 2009; 8 (8): 1921-1933.
25. Harris TB, Launer LJ, Eiriksdottir G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol. 2007; 165 (9): 1076-1087.
26. Qiu C, Cotch MF, Sigurdsson S, et al. Retinal and cerebral microvascular signs and diabetes: the Age, Gene/Environment Susceptibility-Reykjavik Study. Diabetes. 2008; 57 (6): 1645-1650.
27. Jonasson F, Arnarsson A, Eiriksdottir G, et al. Prevalence of age-related macular degeneration in old persons: Age, Gene/Environment Susceptibility- Reykjavik Study. Ophthalmology. 2011; 118 (5): 825-830.
28. Klein R, Meuer SM, Moss SE, Klein BE, Neider MW, Reinke J. Detection of age-related macular degeneration using a nonmydriatic digital camera and a standard film fundus camera. Arch Ophthalmol. 2004; 122 (11): 1642-1646.
29. Klein R, Klein BE, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the Multi-Ethnic Study of Atherosclerosis. Ophthalmology. 2006; 113 (3): 373-380.
30. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N?- (carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997; 99 (3): 457-468.
31. Boehm BO, Schilling S, Rosinger S, et al. Elevated serum levels of N?-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia. 2004; 47 (8): 1376-1379.
32. Zhang X, Frischmann M, Kientsch-Engel R, et al. Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med. 2005; 43 (5): 503-511.
33. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150 (9): 604-612.
34. Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia. 2007; 50 (7): 1409-1417.
35. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye (Lond). 2005; 19 (9): 935-944.
36. Semba RD, Beck J, Sun K, et al. Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of Aging. J Nutr Health Aging. 2010; 14 (7): 507-513.
37. Miura J, Yamagishi SI, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diabetes Complications. 2003; 17 (1): 16-21.
38. Hirata K, Kubo K. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity ofmicroangiopathy in type 2 diabetes. Endocr J. 2004; 51 (6): 537-544.
39. Sharp PS, Rainbow S, Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med. 2003; 20 (7): 575-579.
40. Kilhovd BK, Giardino I, Torjesen PA, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism. 2003; 52 (2): 163-167.
41. Piroddi M, Palazzetti I, Quintaliani G, et al. Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study. J Ren Nutr. 2011; 21 (4): 329-339.
42. Semba RD, Ang A, Talegawkar S, et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur J Clin Nutr. 2012; 66 (1): 3-9.